MiCA for US Stablecoin Issuers Selling Into Europe

A US stablecoin issuer cannot directly issue under MiCA. Regulation (EU) 2023/1114 requires EMT issuers to be EU-authorized credit institutions or electronic money institutions, and ART issuers to be legal persons established in the EU. US issuers selling into Europe have three real paths: stand up an EU EMI subsidiary, partner with an EU-licensed issuer, or geoblock and rely on narrow reverse solicitation.

The wall, stated plainly

MiCA, the Markets in Crypto-Assets Regulation, became applicable for asset-referenced tokens (ART) and e-money tokens (EMT) on June 30, 2024. The full crypto-asset service provider (CASP) regime followed on December 30, 2024. Inside that regime, the issuer-establishment rule is the decisive constraint for US firms:

EMT issuers must be authorized as a credit institution under CRD IV/V or as an electronic money institution (EMI) under EMD2 in an EU member state.
ART issuers must be a legal person established in the EU and authorized by the relevant national competent authority (NCA).

A US LLC or Delaware C-corp does not satisfy either. That is the entire problem for US issuers.

This article vs the EMT-vs-ART explainer

If you want the token-type explainer (what is an EMT, what is an ART, how the categories differ), that lives elsewhere in our knowledge base. This piece is operator-perspective from the US issuer side: given that you already understand the categories, what are your actual paths into the EU market, and what does each one cost?

Path 1: stand up an EU EMI subsidiary

The cleanest path is also the heaviest. The US parent incorporates an EU subsidiary, applies for an EMI license in a chosen member state, and issues the EMT from the subsidiary. The license, once granted, passports to all 27 EU member states plus Iceland, Liechtenstein, and Norway.

What this costs:

Capital. Initial capital requirement for EMIs under EMD2 is 350,000 EUR, plus ongoing own-funds requirements scaled to outstanding e-money.
Time. Authorization typically runs on the order of nine to twelve months from a complete application, with timelines varying by NCA.
Governance. Local senior management, local risk and compliance functions, locally domiciled board members in most NCAs.
Operational. Local segregated reserves at an EU credit institution, daily reconciliation, EU-authorized CASP for any custody work.

What it gets you: full EMT authorization, EU-wide passporting, and the ability to use the EU brand of your stablecoin alongside the US brand. Most large US issuers selling into Europe have chosen this path.

Path 2: partner with an EU-licensed issuer

The white-label path. The US firm partners with an EU-authorized EMI that issues a MiCA-compliant EMT, sometimes branded jointly. The US firm provides technology, distribution, or both; the EU partner holds the license, the reserves, and the issuance authority.

Trade-offs:

Lower fixed cost than standing up an EMI subsidiary. No capital lock-up, no NCA application.
Revenue share. The EU partner takes a meaningful cut of float income.
Brand control. The token is the partner's, even if co-branded.
Strategic risk. The partner can terminate, change pricing, or be acquired.

This path fits issuers with limited EU revenue at stake or those testing the EU market before committing to a subsidiary.

Path 3: geoblock and rely on reverse solicitation

The narrowest path. Do not actively solicit EU customers. Geoblock at IP and KYC. Serve only EU users who arrive on their own initiative.

This relies on MiCA's reverse-solicitation exemption, which is narrow and getting narrower. The European Securities and Markets Authority (ESMA) has issued guidance interpreting reverse solicitation strictly: a single piece of EU-targeted marketing breaks the exemption for the entire EU market (per ESMA's published Q&A on reverse solicitation under MiCA).

Trade-offs:

Zero EU regulatory burden.
Zero ability to grow the EU market.
High operational risk that a single Europe-targeted tweet, ad, or partnership breaks the exemption.

This path works for issuers who genuinely do not want EU users and have the operational discipline to keep marketing US-only.

EMT reserve requirements (if you go Path 1 or 2)

MiCA EMT reserve rules look like a stricter version of a US bank-grade money-market structure:

1:1 reserves in highly liquid assets.
Daily reconciliation between tokens outstanding and reserve balance.
Segregation from the issuer's own assets.
Custody by an EU credit institution or an authorized CASP.
Reserve composition capped to deposits and short-term high-quality assets, with concentration limits per credit institution.
Significant EMT designation triggers heightened supervision by the European Banking Authority (EBA) once thresholds are crossed (200,000 transactions per day or 100m EUR transaction volume per day, per Article 43 of Regulation (EU) 2023/1114).

White paper publication, host-state notification, ongoing reporting, and consumer-disclosure rules all apply on top.

What about USD-denominated EMTs?

MiCA does not require EMTs to be Euro-denominated. A USD EMT issued by an EU-licensed EMI is permitted and is, in fact, the structure several US issuers have chosen for their EU offering. The catch: significant non-Euro EMTs face additional restrictions on transaction-volume thresholds intended to protect monetary sovereignty. Above the daily transaction-count and value thresholds set in MiCA Article 23, the issuer must restrict use of the non-Euro EMT as a means of exchange within the EU.

Compliance checklist for the US issuer evaluating EU entry

Quantify EU revenue at stake. Below a threshold, Path 3 (geoblock + discipline) wins.
Decide on Euro vs USD denomination. USD is allowed but capped at scale.
Select an NCA. Ireland, Netherlands, France, and Germany have been the most active jurisdictions for stablecoin authorizations under MiCA so far.
Identify a reserve custodian. EU credit institution or authorized CASP.
Build the white paper and host-state notification stack.
Build supervisory-reporting infrastructure (daily reconciliation, monthly reporting, ad hoc disclosures).

Where this interacts with CLARITY and GENIUS

Operators with both US and EU exposure run two parallel frameworks. GENIUS (US, enacted) and CLARITY (US, proposed) govern issuance domestically. MiCA governs EU distribution. The two do not align on issuer establishment, holder yield, or reserve composition rules in identical ways. Operators should not assume that compliance with one shortens the path to the other. It does not.

The decision tree

Do you expect more than de minimis EU revenue in the next 24 months? If no, choose Path 3.
If yes, is your EU revenue thesis large enough to justify 350,000 EUR plus ongoing own-funds plus governance? If yes, Path 1. If no, Path 2.
Once chosen, pick your NCA based on speed, supervisory style, and existing-issuer track record.
Build for Euro plus USD denomination from day one if your US product is USD-denominated.

Bottom line

MiCA is not a friendly framework for US stablecoin issuers, but it is a navigable one. The wall is the EU-establishment requirement, and the three paths around it (EMI subsidiary, white-label partner, geoblock) are well understood and have been used by issuers already in the market. The right path depends on EU revenue at stake and the issuer's appetite for regulated-entity overhead. There is no compliant fourth path. Direct issuance from a US entity is not on the menu.